Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AiCuris, 4SC Discovery and CRELUX Announce Drug Discovery Collaboration

Published: Tuesday, November 05, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
AiCuris will use the high quality integrated drug discovery platform i2c of CRELUX and 4SC Discovery to identify novel therapeutics for infectious diseases.

4SC AG has announced that 4SC Discovery GmbH, CRELUX GmbH and AiCuris GmbH & Co. KG have started a drug discovery collaboration to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases.

The collaboration is a further proof for the innovative capacity and the high quality standard of the joint integrated drug discovery platform i2c ('idea-to-candidate'), operated by 4SC Discovery and CRELUX.

Based on i2c, CRELUX and 4SC Discovery will discover and optimize small molecule compounds with the goal to deliver high quality drug candidates for a novel anti-infectious therapeutic approach by AiCuris.

A virtual screening approach using 4SC's proprietary 4Scan® method will be performed to identify various inhibitors to the therapeutic target. Compounds identified as potential inhibitors of the respective target will be verified by using both, established assays at AiCuris and the INTRACT in vitro screening systems at CRELUX.

In the course of the further discovery process, protein structures of verified hits with the target will be solved by i2c to enable rational design and guide the further chemical optimization.

Prof. Helga Rübsamen-Schaeff, CEO of AiCuris comments: 'We are dedicated to fill our early pipeline with highly innovative next generation drugs against infectious diseases with high medical need and which are also active against resistant pathogens. These may be derived from in house research, from licensing or from collaborations.'

Dr. Holger Zimmermann, Managing Director and Chief Scientific Officer at AiCuris adds: 'Based on our good experience in collaborating with 4SC we expect to identify soon first promising hits for further evaluation in our screening cascades. This collaboration is an important contribution to our in house research efforts and supports our goal to discover highly efficacious drugs which help to solve major problems in treating infectious diseases.'

Dr. Michael Schaeffer, Executive Director Strategy and Business of CRELUX GmbH, comments: 'This collaboration is a further proof of the value i2c brings to its clients' drug discovery programmes. With Aicuris, we see a perfect fit of ideas, technologies and know-how and are especially pleased to have gained yet another innovative and reknowned biotech company from Germany as a partner. With this partnership, CRELUX and 4SC Discovery continue to build on their joint strategy to position themselves as premium solution providers to the global pharma and biotech industry covering the complete drug discovery value chain.'

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, comments: 'The selection of i2c as drug discovery platform for AiCuris is an important step in our strategy to become Europe's leading partner for innovative and high quality drug discovery projects. We are particularly delighted, since this new collaboration is built on our long-term trustful relationship and former successful collaborations between AiCuris and 4SC, now targeting next generation high therapeutic needs in antiinfective drug discovery.'

The i2c platform operates on a seamlessly integrated suite of technologies including virtual high throughput screening, molecular modelling, X-ray crystallography, in vitro and cell based screening, medicinal chemistry and pharmacology.

CRELUX and 4SC Discovery are offering integrated drug discovery solutions to clients from the pharmaceutical and biotechnology industry covering the entire value chain of early-stage pharmaceutical research and drug discovery.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!